Yabao Pharmaceutical Group Co., Ltd. established in 1978, it went public on the Shanghai Stock Exchange in 2002. Yabao Pharmaceutical adheres to the strategic approach of "Pediatrics First, Adult Medicines Supplement, Investment & Innovation." Guided by clinical demands, led by internationalization, and driven by talent and technology, the company focuses on pediatrics. It has implemented a comprehensive layout in various areas such as innovative drugs, complex generic drugs, Traditional Chinese Medicine, and comprehensive health products. The company has established a national-level enterprise technology center, post-doctoral research stations, and academician workstations. It possesses over 1000 intellectual property rights, including authorized patents, registered trademarks, and copyrights. The company has established nine major production bases and three R&D bases，and multiple production lines have been certified by developed countries such as the United States, Germany, and Japan.